Disulfide locked variants of factor VIIa with a restricted β-strand conformation have enhanced enzymatic activity

被引:10
作者
Maun, HR
Eigenbrot, C
Raab, H
Arnott, D
Phu, L
Bullens, S
Lazarus, RA
机构
[1] Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA
[4] Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany
关键词
coagulation factor VIIa; tissue factor; serine protease; zymogen; hemostasis; disulfide; allostery;
D O I
10.1110/ps.041097505
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteolytic processing of zymogen Factor VII to Factor VIIa (FVIIa) is necessary but not sufficient for maximal proteolytic activity, which requires an additional allosteric influence induced upon binding to its cofactor tissue factor (TF). A key conformational change affecting the zymogenicity of FVIIa involves a unique three-residue shift in the position of beta-strand B2 in their zymogen and protease forms. By selectively introducing new disulfide bonds, we locked the conformation of these strands into an active TF(.)FVIIa-like state. FVIIa mutants designated 136:160, 137:159, 138:160, and 139:157, reflecting the position of the new disulfide bond (chymotypsinogen numbering), were expressed and purified by TF affinity chromatography. Mass spectrometric analysis of tryptic peptides from the FVIIa mutants confirmed the new disulfide bond formation. Kinetic analysis of amidolytic activity revealed that all FVIIa variants alone had increased specific activity compared to wild type, the largest being for variants 136:160 and 138:160 with substrate S-2765, having 670- and 330-fold increases, respectively. Notably, FVIIa disulfide-locked variants no longer required TF as a cofactor for maximal activity in amidolytic assays. In the presence of soluble TF, activity was enhanced 20- and 12-fold for variants 136:160 and 138:160, respectively, compared to wild type. With relipidated TF, mutants 136:160 and 137:159 also had an approximate threefold increase in their V-max/K-m values for FX activation but no significant improvement in TF-dependent clotting assays. Thus, while large rate enhancements were obtained for amidolytic substrates binding at the active site, macromolecular substrates that bind to FVIIa exosites entail more complex catalytic requirements.
引用
收藏
页码:1171 / 1180
页数:10
相关论文
共 62 条
[1]   The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor [J].
Banner, DW ;
DArcy, A ;
Chene, C ;
Winkler, FK ;
Guha, A ;
Konigsberg, WH ;
Nemerson, Y ;
Kirchhofer, D .
NATURE, 1996, 380 (6569) :41-46
[2]   THE SINGLE-CHAIN FORM OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR HAS CATALYTIC ACTIVITY - STUDIES WITH A MUTANT ENZYME THAT LACKS THE CLEAVAGE SITE [J].
BOOSE, JA ;
KUISMANEN, E ;
GERARD, R ;
SAMBROOK, J ;
GETHING, MJ .
BIOCHEMISTRY, 1989, 28 (02) :635-643
[4]   SYNTHETIC SUBSTRATES FOR HUMAN FACTOR-VIIA AND FACTOR-VIIA-TISSUE FACTOR [J].
BUTENAS, S ;
RIBARIK, N ;
MANN, KG .
BIOCHEMISTRY, 1993, 32 (26) :6531-6538
[5]   How factor VIIa works in hemophilia [J].
Butenas, S ;
Brummel, KE ;
Bouchard, BA ;
Mann, KG .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (06) :1158-1160
[6]   Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia [J].
Butenas, S ;
Brummel, KE ;
Paradis, SG ;
Mann, KG .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :123-129
[7]   THE COAGULATION CASCADE - INITIATION, MAINTENANCE, AND REGULATION [J].
DAVIE, EW ;
FUJIKAWA, K ;
KISIEL, W .
BIOCHEMISTRY, 1991, 30 (43) :10363-10370
[8]  
DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1
[9]  
DENNIS MS, 1994, J BIOL CHEM, V269, P22129
[10]   Peptide exosite inhibitors of factor VIIa as anticoagulants [J].
Dennis, MS ;
Eigenbrot, C ;
Skelton, NJ ;
Ultsch, MH ;
Santell, L ;
Dwyer, MA ;
O'Connell, MP ;
Lazarus, RA .
NATURE, 2000, 404 (6777) :465-470